Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma

NCT00964080 is registered in ClinicalTrials.gov with Mebiopharm Co., Ltd as lead sponsor.

NCT NCT00964080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00964080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma
Lead sponsor
Mebiopharm Co., Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
May 31, 2009
Completion date
April 30, 2015
Enrollment
62 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma